A systematic approach to maximising the manufacturing quantity and transduction activity of lentiviral vectors

 

Lentiviral vectors are central to the application of many exciting gene therapy strategies, including gene-supplementation (e.g. SCID) and immunotherapies such as CAR T cells, used in cancer treatment. Two factors currently limiting wider development of these approaches are the yield and scalability of lentiviral production systems, and relatively low infectivity in T cells. We set out to systematically improve these limitations.

 

Download the award winning poster to read more...